Cargando…
Does route of administration affect the outcome of TNF antagonist therapy?
The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833461/ https://www.ncbi.nlm.nih.gov/pubmed/15228617 http://dx.doi.org/10.1186/ar996 |
_version_ | 1782178391886135296 |
---|---|
author | Schwartzman, Sergio Morgan, G James |
author_facet | Schwartzman, Sergio Morgan, G James |
author_sort | Schwartzman, Sergio |
collection | PubMed |
description | The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy. |
format | Text |
id | pubmed-2833461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28334612010-03-08 Does route of administration affect the outcome of TNF antagonist therapy? Schwartzman, Sergio Morgan, G James Arthritis Res Ther Review The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy. BioMed Central 2004 2004-06-21 /pmc/articles/PMC2833461/ /pubmed/15228617 http://dx.doi.org/10.1186/ar996 Text en Copyright ©2004 BioMed Central Ltd |
spellingShingle | Review Schwartzman, Sergio Morgan, G James Does route of administration affect the outcome of TNF antagonist therapy? |
title | Does route of administration affect the outcome of TNF antagonist therapy? |
title_full | Does route of administration affect the outcome of TNF antagonist therapy? |
title_fullStr | Does route of administration affect the outcome of TNF antagonist therapy? |
title_full_unstemmed | Does route of administration affect the outcome of TNF antagonist therapy? |
title_short | Does route of administration affect the outcome of TNF antagonist therapy? |
title_sort | does route of administration affect the outcome of tnf antagonist therapy? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833461/ https://www.ncbi.nlm.nih.gov/pubmed/15228617 http://dx.doi.org/10.1186/ar996 |
work_keys_str_mv | AT schwartzmansergio doesrouteofadministrationaffecttheoutcomeoftnfantagonisttherapy AT morgangjames doesrouteofadministrationaffecttheoutcomeoftnfantagonisttherapy |